Protein is having a moment.
Walk any grocery aisle, and you’ll find protein sodas, protein popcorn, protein pancakes, and coffee chains adding protein cold foam to lattes.
Nearly 60% of global consumers now say they seek protein across foods and occasions, and “protein-maxxing” has saturated the market to the point that manufacturers are facing whey shortages. Social media is flooded with content showing protein hacks, and on the next swipe, a viral video warning that the chicken on your plate might kill you.
As cancer professionals, it’s tempting to roll our eyes at the hype, to try to ignore it or hope it goes away, but instead these trends are an opportunity to create a conversation around two of the key pillars in lifestyle medicine: exercise and nutrition.
For patients in our clinics, the protein buzz inadvertently points to one of the most under-addressed problems in oncology. Muscle.
While the internet argues about protein candy, our patients are quietly losing skeletal muscle – and it is costing them.
Sarcopenia, the progressive loss of muscle mass and function, is among the most common and least discussed comorbidities in cancer care. Prevalence varies by tumor type and stage, but in some populations it reaches half of patients – and treatment accelerates it. In one esophageal cancer cohort, sarcopenia prevalence rose from 29.5% before neoadjuvant therapy to 63.9% during treatment (Panje, 2019).
Why should this change how we practice? Because muscle is not cosmetic. It is a clinical organ system with prognostic weight:
- Treatment tolerance. Sarcopenic patients show significantly higher rates of grade 3–4 toxicities – 36.2% versus 21.1% in one chemoradiotherapy cohort – driving dose reductions and treatment interruptions (Xu, 2021).
- Survival. Sarcopenia is independently associated with decreased overall survival across multiple tumor types (Xu, 2021).
- Function and independence. Muscle is the reserve our patients draw on to tolerate surgery, recover from treatment, and return to the lives they are fighting for.
Timing matters more than ever. As GLP-1 receptor agonists reshape weight management, including for our patients, rapid weight loss without adequate protein and resistance training reduces lean mass along with fat. We are entering a time when protecting muscle must be an explicit clinical goal, not a hoped-for side effect. This also means we need practical ways to identify and monitor muscle loss before problems escalate. Simple strategies like measuring grip strength, timing sit-to-stand tests, or reviewing muscle mass on CT scans already available in oncology can help us track changes and intervene early. By incorporating these tools into routine practice, clinicians can act proactively and help patients preserve function and independence.
The gap between what patients need and what they hear
ESPEN guidelines recommend a minimum protein intake of 1.0 g/kg/day for cancer patients, with 1.2–1.5 g/kg/day often needed to maintain or restore lean body mass (Arends, 2017), and trials are now testing intakes as high as 2.0 g/kg/day in patients with colorectal cancer (Ford, 2024). For a 70 kg (154 lb) patient, that’s about 70 grams per day as a floor and 84 to 105 grams as a target. Many patients don’t even reach the floor. Aging compounds the challenge because anabolic resistance means older adults need more protein per meal to trigger the same muscle-building response as younger bodies.
Outdated fears persist in clinics. Patients still ask whether protein “feeds the tumor.”
A patient might say,
“My neighbor told me extra protein will speed up my cancer,” or “I heard too much protein will damage my kidneys.”
These concerns are common.
Evidence is increasingly reassuring: a 2024 umbrella review for the German Nutrition Society concluded that higher protein intake may not be linked to colorectal or breast cancer risk, with insufficient evidence for other types (Kühn, 2024).
Higher protein intake is not the villain patients fear; under-consuming it during treatment may be the greater risk. When patients bring up these myths, a simple response can help:
“Recent research has not shown that higher protein intake increases cancer growth or harms your kidneys during treatment. In fact, getting enough protein helps your body handle treatment better and supports recovery.”
Yet some patients restrict protein due to unfounded kidney concerns, and others were told to “eat whatever you can keep down.”
While compassionate during acute treatment, this advice often becomes a long-term pattern that undershoots protein for years into survivorship.
Confusion now cuts both ways.
This summer, headlines claimed eating less protein slows aging, based on a review of over 350 studies mostly in animal models (Knopf and Lamming, 2026). In flies and mice, protein restriction extends lifespan.
In humans, no study has shown longer life on less protein or faster aging on more. Human data points the opposite way: in about 3,600 older adults, those with the most muscle mass were about 20% less likely to die over more than a decade than those with the least (Srikanthan, 2014).
“You don’t need extreme amounts” and “eat less protein” are different. For an older adult with cancer, following the second is a fast track to the outcome we want to avoid.
Here is the opportunity: our patients are already hearing about protein. The cultural moment has done something clinicians have struggled to do for decades – it made a nutrient interesting. Patients will ask about the protein products in their feeds. Every one of those questions is an open door.
Walking through the door: practical guidance
When patients bring the buzz to us, we can meet it with clinical substance. While we may be tempted to immediately refer to a clinical dietitian, spending a few minutes addressing the concern ourselves keeps patients on the right track – and makes the eventual dietitian referral land better, because they arrive curious instead of skeptical.
Here are quick ways to support that conversation. Ask your dietitian team for simple handouts – they keep the conversation moving and give patients a tangible tool to leave with.
1. Ask one question. “Tell me what you eat for breakfast.” It takes fifteen seconds and tells you more about protein distribution than most intake forms. Toast and coffee is the most common answer – and a near-zero-protein start to the day.
2. Anchor the target to their body. “About 1.2 grams per kilogram” means nothing to most patients. “Your target is roughly 80 grams a day – think 25 to 30 grams at each meal” is actionable. Offer a sense of what this looks like on the plate: 25–30 grams could be three eggs plus a serving of Greek yogurt, a cup of cottage cheese with fruit and nuts, a can of tuna on whole-grain bread, four ounces of chicken breast, or a tofu and bean stir-fry over rice.
Distribution matters: spreading protein across meals better supports muscle protein synthesis than a dinner-heavy pattern, especially in older adults facing anabolic resistance.
3. Lead with food, welcome the tools. Eggs, dairy, fish, poultry, beans, lentils, tofu, and soy all count – and yes, patients can be reassured that soy is safe, including after hormone-sensitive cancers. Protein powders and fortified products are reasonable tools when appetite, taste changes, or fatigue make whole-food targets unrealistic.
The trend’s products aren’t the enemy; unexamined reliance on them is.
4. Pair protein with resistance. Protein is the raw material; loading is the signal. Without resistance exercise, additional protein cannot fully translate into preserved muscle. The prescription is the same one ACSM has given us: strength training at least twice weekly, scaled to the patient in front of you (Campbell, 2019).
Chair-supported movements, resistance bands, bodyweight exercises, and even repeated sit-to-stand from a chair all count as resistance exercise for frail or treatment-limited patients. A referral to exercise oncology or physical therapy turns this from advice into a plan.
5. Refer and measure. Oncology dietitians remain one of the most underutilized referrals in cancer care. And whether by CT-based muscle analysis we already have in hand, grip strength, or simple sit-to-stand tests, we can begin treating muscle as the vital sign it is.
For workflow, consider adding a muscle health prompt to your intake checklist – such as a single grip strength test or a short question about recent declines in function. Embedding a quick muscle measure or dietitian review in routine follow-up visits takes less than a minute and flags declining reserves before patients lose ground. Even a simple note template cue like “muscle status/dietitian discussed? Y/N” can help keep this front of mind in busy clinics.
Use the moment
Market forecasters predict the protein-maxxing trend will fade before the decade ends. The clinical need will not.
Trends come with noise. Protein sodas will not save our patients, and 200-gram days remain unnecessary for most. But dismissing the buzz wholesale would waste the most useful thing: our patients are finally curious about the nutrient their outcomes may depend on most.
The next time a patient asks about the protein product they saw online, consider it a clinical opening, not a distraction. Somewhere between the hype and the eye-roll is a conversation about muscle – and it’s one of the highest-yield conversations in our clinic.
References
- Arends J, Bachmann P, Baracos V, et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2017;36(1):11–48.
- Kühn T, Kalotai N, Amini AM, et al. Protein intake and cancer: an umbrella review of systematic reviews for the evidence-based guideline of the German Nutrition Society. Eur J Nutr. 2024;63(5):1471–1486.
- Srikanthan P, Karlamangla AS. Muscle mass index as a predictor of longevity in older adults. Am J Med. 2014;127(6):547–553.
- Knopf BA, Lamming DW. The hallmarks of protein and amino acid restriction in aging and longevity. Cell Press Blue. 2026;100079.
- Panje CM, et al. Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: a SAKK 75/08 substudy. Radiat Oncol. 2019;14:166.
- Xu YY, Zhou XL, et al. Association of sarcopenia with toxicity and survival in postoperative recurrent esophageal squamous cell carcinoma patients receiving chemoradiotherapy. Front Oncol. 2021;11:655071.
- Ford KL, et al. Feasibility of two levels of protein intake in patients with colorectal cancer: the PRIMe randomized controlled pilot trial. ESMO Open. 2024.
- Campbell KL, Winters-Stone KM, Wiskemann J, et al. Exercise guidelines for cancer survivors: consensus statement from the international multidisciplinary roundtable. Med Sci Sports Exerc. 2019;51(11):2375–2390.
- Market data: Innova Market Insights, protein market trends 2026
- Fortune, June 2026, on protein-maxxing and whey shortages
You can also read:
